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Abstract
Turkey has signiﬁcant geographical and socio-economic differences throughout a vast area of the country. These characteristics affect
the epidemiology of infectious diseases, some of which are rarely seen in western Europe. However, effectively implemented control
measures have resulted in decreased rates of many community-acquired infections, including tuberculosis and malaria, that were
major health problems only a few decades ago. There are high rates of antimicrobial resistance in various nosocomial isolates of
Gram-positive and Gram-negative bacteria. A recently implemented, nationwide, electronic resistance surveillance system in hospitals
is expected to produce reliable data, and possibly will help to develop an effective strategy to decrease antimicrobial resistance in
bacteria that currently plague many tertiary-care hospitals in the country. This article summarizes the most frequently encountered
community-acquired infections, and gives an overview of current antimicrobial resistance in both outpatient and hospital settings in
Turkey.
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Introduction
Turkey is at the crossroads between Europe, Asia, and
Africa. This geographical situation has not only had signiﬁcant
economic and cultural impacts over the centuries, but has
also been responsible for the epidemiology of various infec-
tious diseases occurring throughout the country. As of 2012,
Turkey has 75 million inhabitants, and the population growth
rate is 13.5 per thousand. Three-quarters of the country’s
population resides in cities and large towns, and one-quarter
resides in villages and rural areas (http://www.tuik.gov.tr/
IcerikGetir.do?istab_id=139).
According to the data released by the Statistical Institute
of Turkey, 4226 patients lost their lives because of infectious
diseases in Turkey in 2008, and 102 528 and 33 188 died
because of circulatory system disorders and neoplasms,
respectively. Thus, communicable diseases contributed to
mortality in <2% of all deaths in the country (http://
www.tuik.gov.tr/IcerikGetir.do?istab_id=1). The current
review focuses on the epidemiology of the most common
infectious diseases in Turkey, including data on regional anti-
biotic resistance patterns.
Bacterial Infections
Brucellosis
Brucellosis is a zoonotic infection transmitted to humans
from infected animals and animal food products. In 2002,
17 765 cases of human brucellosis were reported in Turkey,
with a prevalence rate 25 per 100 000 population [1]. How-
ever, this ﬁgure almost halved to 9324 cases with a preva-
lence rate of 13 per 100 000 in 2009, owing to extensive
control efforts [2]. The disease is mostly prevalent in the
central and south-eastern parts of the country, where animal
husbandry is an important source of living [3]. Brucella melitensis
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accounts for the majority of cases of brucellosis in humans
in Turkey, followed by Brucella abortus, the second most fre-
quent agent [4].
Brucellosis has traditionally been included in the differential
diagnosis of persistent fever in both adults and in children [5],
including those with neutropenia and cancer [6–9], and
causes a signiﬁcant threat to laboratory workers [4,10]. The
various complications and rare forms of clinical presentation
have been extensively reported [11–14]. Several papers have
been published on various modalities of treatment, including
early reports on the ineffectiveness of quinolone monothera-
py and the comparative efﬁcacy between quinolone plus
rifampin combinations and the classical WHO-suggested regi-
men of doxycycline plus rifampin [15–17].
Tularaemia
Tularaemia had been historically known to cause sporadic
outbreaks, particularly in the north-western parts of the
country [18]. However, tularaemia has now become an
emerging zoonotic disease disseminating over a wider geo-
graphical area in Turkey [19–22]. Genetic analyses of Franci-
sella tularensis recovered from various sites in the country
showed close linkages with neighbouring countries such as
Bulgaria [23]. Most of the cases described were of the pha-
ryngeal type of disease, and the classical case description
included a patient with fever, sore throat and cervical lymph-
adenopathy who failed to respond to b-lactam antibiotic
therapy [21]. Furthermore, seroepidemiological evidence of
the infection was detected in villagers dealing with farming
and animal husbandry in the eastern part of the country
[22].
The disease is prominent during winter and autumn;
unchlorinated and contaminated water is the major cause of
dissemination for oropharyngeal infection [24]. Occasionally,
the oculoglandular form has been reported, owing to wash-
ing of the face with contaminated water. Although the
microorganism could not be cultured from the suspected
water sources, molecular evidence of tularaemia was found
by PCR on the same samples [25]. F. tularensis ssp. holarctica
(type B) was found to be the predominant subtype in Turkey
[23]. Fishing, animal farming and hunting were proved to be
additional risk factors in a study performed in an endemic
area with an overall attack rate of 2.3 per 1000 population
[26].
In an in vitro study, 39 isolates of F. tularensis were suscep-
tible to aminoglycosides, tetracyclines, chloramphenicol, rif-
ampicin, and ﬂuoroquinolones, but were resistant to
macrolides, clindamycin, and b-lactams. Furthermore, ﬂuor-
oquinolones, levoﬂoxacin in particular, were found to have
the lowest MIC50 and MIC90 values [27].
Tuberculosis (TB)
Currently, the WHO estimates that 12 million people are liv-
ing with tuberculosis (TB) worldwide (http://www.global-
healthfacts.org/data/topic/map.aspx?ind=16). According to a
recent WHO report based on the geographical proﬁle in 2010,
the prevalence of the disease per 100 000 population was 5.9
in Germany, 15 in the UK, 18 in Spain, 29 in Poland, and 24 in
Turkey (http://apps.who.int/ghodata/?vid=500). Overall, during
the last 15 years, there has been a steady decline in the preva-
lence of TB cases in Turkey [28]; the rate of <25 cases per
100 000 means that the country is classiﬁed as a low-endemic-
ity region according to the WHO deﬁnition. However, TB still
continues to be included in the differential diagnosis of fever of
unknown origin in clinical practice in Turkey [29–31].
The prevalence of multidrug-resistant (MDR) Mycobacterium
tuberculosis (deﬁned as isolates that are non-susceptible to iso-
niazid and rifampicin) is relatively low [32]; the reported ﬁg-
ures vary between 2% and 21% [33–36]. According to the
‘Fight against Tuberculosis 2009 Report’ of the Turkish Minis-
try of Health (MoH), the frequency of MDR strains was 3% in
new cases, whereas it was reported to be 18% in previously
treated patients. Overall, this report indicated that the rate of
MDR TB was 5% [37]. On the other hand, extensively drug-
resistant TB (deﬁned as MDR isolates resistant to any ﬂuor-
oquinolone and one or more of the three injectable anti-TB
drugs: capreomycin, kanamycin, and amikacin) was reported
to be approximately 0–2.5% in Turkey [38,39].
Lyme disease
There have been many case reports of Lyme disease from
Turkey [40–43]. The seropositivity rate was reported to be
17% in patients with a history of tick bite in central Anatolia
[44], and Borrelia burgdorferi, the agent of Lyme disease, was
found to be active in Ixodes ricinus ticks in Turkey [45]. How-
ever, solid data seem to be substantially lacking for the epi-
demiology of Lyme disease in Turkey.
Rickettsioses
In the past history, rickettsioses had subtantial impacts on
the Turkish population [46–48]. The use of molecular genetic
tools and cell culture assays have signiﬁcantly improved the
discovery of new agents, and consequently three new ehrli-
chioses and 12 rickettsioses have been described worldwide
since 1980 [49]. On the other hand, old rickettsioses, such
as epidemic typhus or scrub typhus, have re-emerged
because of poor living standards [50].
A few small clusters of patients with disease related to
Rickettsia conorii infection were observed in different parts of
Turkey in the last decade [51–53]. Also, there were sporadic
case reports of rickettsioses throughout the country [54,55].
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Viral Infections
Human immunodeﬁciency virus (HIV) infection
In 2010, 32.4 million people were living with HIV worldwide,
and 1.8 million died of AIDS-related illnesses (http://
www.who.int/gho/HIV/en/index.html). The ﬁrst case in Tur-
key was reported in 1985 [56], and, by the end of December
2011, there were 5224 conﬁrmed cases (http://pozitifya
sam.org/tr/turkiyede-HIV-AIDS.html). Although it is very
probable that there has been under-reporting, the current
prevalence of the disease is accepted to be <0.1% [57–59].
Turkey seems to have the lowest HIV prevalence rate after
Bosnia and Herzegovina in the Balkan region, and the most
frequent route of transmission is the heterosexual one [60].
Inadequate knowledge on sexually transmitted diseases, a rel-
atively younger population, ease of travel, poor socio-eco-
nomic conditions, an increase in the number of unregistered
sex workers and intravenous drug use have all been
reported to contribute to the prevalence of HIV infection in
Turkey [61–64]. On the other hand, several nationwide
awareness and counselling programmes for HIV and related
diseases are available from different non-governmental orga-
nizations. Currently, all HIV-infected patients are covered by
the national insurance system, which provides free access to
all diagnostic procedures and antiretroviral treatment, includ-
ing the up-to-date theraputic regimens.
Crimean–Congo haemorrhagic fever (CCHF)
Crimean–Congo haemorrhagic fever is a tick-borne infection
caused by the genus Nairovirus from the family Bunyaviridae
[65]. The disease was initially recognized by Russian scien-
tists among Soviet military recruits in 1940s [66], and Cri-
mean haemorrhagic fever was subsequently found to be
indistinguishable from Belgian Congo fever [67]. Thus, the
two names were combined.
The virus has been known to affect human populations in
neighbouring countries such as Bulgaria [68], Greece [69],
Iraq [70], and Iran [71]. The ﬁrst symptomatic human CCHF
case was noted in 2002 in Turkey, with serious impacts on
healthcare workers [72–74]. Consequently, awareness of the
disease has been raised among medical personnel [75]. In
2009, c. 1300 cases were reported, with a mortality rate of
4.8% [76]. The large number of cases admitted to hospitals
during the epidemic season of the disease in certain areas has
signiﬁcantly increased the workload of blood banks and trans-
fusion centres, owing to excessive consumption of blood and
blood products for the management of the disease [77].
The potential vectors for CCHF transmission in Turkey
are Rhipicephalus bursa, Hyalomma marginatum marginatum
and Haemaphysalis parva ticks [78]. Although CCHF is usually
diagnosed during spring and summer, when ticks are active,
the disease has also been reported during the winter season
[79].
The clinical presentation may range from a mild clinical
course to severe and fatal progression. Recent outbreaks in
Turkey have provided opportunities to detail the characteris-
tics of the disease [80–86]. Patients frequently present with
fever, fatigue, generalized pain, myalgia, nausea and vomiting,
and diarrhoea, and in severe cases epistaxis, haematemesis,
melena, haematuria, gingival bleeding, vaginal bleeding, pete-
chiae or ecchymosis are also seen. In the latter cases, death
occurs as a result of multi-organ failure, disseminated intra-
vascular coagulation, and circulatory shock [87,88]. A recent
seroepidemiological survey estimated that up to 88% of
infections were subclinical [89].
The use of ribavirin remains controversial; however, the
WHO recommends the use of both oral and intravenous
formulations of ribavirin in the management of CCHF (http://
www.Who.Int/mediacentre/factsheets/fs208/en/). Recently,
many studies have been published on unsettled issues regard-
ing the use of ribavirin for CCHF management [88,90–94].
Hantavirus infections
At least ﬁve hantavirus subtypes—Puumala, Dobrava, Saar-
emaa, Tula and Seoul subtypes—are found across Europe
[95]. The virus is transmitted to humans through infected
rodents and their excreta, in contrast to other genera of the
family Bunyaviridae, which are usually transmitted through ar-
thropods [96]. Hantaviruses cause two different types of dis-
ease in humans: haemorrhagic fever with renal syndrome
(HFRS) and hantavirus pulmonary syndrome. HFRS is seen
mainly in the Eurasian region, and hantavirus pulmonary syn-
drome is usually detected in the Americas [97].
Although there have been recent reports on hantavirus
infections, there are no nationwide data on this disease. In
2009, 12 conﬁrmed HFRS cases were reported from Zongul-
dak province, located in north-western Turkey. Although the
results showed serological positivity for the Puumala subtype,
the speciﬁcity of this test remains unconﬁrmed, owing to
cross-reactivity among hantavirus subtypes. Another limita-
tion of this study was the negative RT-PCR result; conse-
quently, sequence analysis could not be performed [98]. Five
cases of Dobrava subtype infection were reported from Gire-
sun (two cases), a city located in north-eastern Turkey [99],
Istanbul (two cases) [100,101], and Ankara [102]. The only
death occurred in one of the Istanbul cases. In an animal
study, the Puumala subtype was found in 6% of Microtus wild
rodents in Trabzon and Izmir provinces, located in the north-
eastern and western parts of the country, respectively [103].
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West Nile virus (WNV) infection
West Nile virus (WNV), a member of the Japanese encepha-
litis virus antigenic complex, causes a wide range of clinical
pictures, from asymptomatic disease to severe meningitis and
encephalitis. Most of the people infected with WNV are
asymptomatic, and symptoms are seen in only 20–40% of
infected patients. Although fever is one of the characteristic
symptoms caused by WNV, some patients report low-grade
fever or no fever at all [104].
The initial evidence of WNV infection in Turkey obtained
from a seroprevalence survey was obtained in 1977 [105].
There had been several case reports of WNV infection by
the end of summer 2010 [106–109]. Thirty-ﬁve probable and
12 conﬁrmed cases, with 21% mortality, were reported from
15 provinces, mainly located in the western part of the coun-
try [110]. WNV infections were included in the list of
national notiﬁable diseases as of April 2011.
Seroprevalence studies indicated that serological evidence
of WNV infection was present in approximately 1% of
healthy blood donors [111,112]. Although WNV was not
detected in the usual vectors, such as Culex pipiens, Ochlerota-
tus caspius, and Aedes spp., in the south-eastern provinces of
Turkey, 16% of 181 human subjects screened in the same
region were found to be seropositive [113].
Currently, there is no nationwide donor screening pro-
gramme for WNV for organ transplantation.
Hepatitis A–D viruses
In 2011, the annual incidence rates of acute hepatitis A virus
(HAV) and acute hepatitis B virus (HBV) infections, respec-
tively, were 5.21 and 3.79 per 100 000 population in Turkey.
Although mortality was not recorded for HAV infection, six
patients lost their lives because of acute HBV infection and
ﬁve because of hepatitis C virus (HCV) infection in 2011
(data from Turkish MoH, personal communication with S.
Tosun). In 2008, 79% of acute HAV infections were detected
among the younger age group (<15 years), and 93% and
97%, respectively, of acute HBV and HCV infections were
seen among those who were >15 years of age. Currently,
HAV infection still appears to be a childhood disease in Tur-
key, and HAV vaccine has been recently included in the
National Immunization Programme. Thus, a consequent
decrease in the incidence of the disease should be expected.
The main transmission route of HBV is through hetero-
sexual contact [114]. The prevalence of HBV infection is
higher (3–10%) in the eastern and south-eastern parts of
Turkey [115,116], where the general socio-economic level of
the population is lower than in the rest of the country. On
the other hand, the prevalence rates vary between 1.7% and
3% in the western provinces [117–121]. This ﬁgure makes
the central and western parts of the country low-endemicity
and moderate-endemicity regions, and the eastern and
south-eastern provinces high-endemicity regions, according
to the WHO classiﬁcation, in which a <2% threshold deter-
mines low endemicity and >8% high endemicity. Genotype D
is known to be the predominant HBV genotype in Turkey
[122,123]. HBV vaccination has been included in the National
Immunization Programme for newborns and young children
since 1998, and the cost of the vaccine is also reimbursed
for those who are at high risk of acquiring the infection
[124].
Although hepatitis D virus (HDV) infection prevalence
seems to have declined recently, it is still a signiﬁcant public
health problem in Turkey [125]. The disease is frequent in
the eastern and south-eastern provinces [126], and HDV
seroprevalence is 3–5% among HBV carriers [127–129],
16–45% in chronic hepatitis cases [128,130], and 45% in
patients with cirrhosis [128]. HDV-1 seems to be the
predominant genotype in patients with HDV infections in
Turkey [131,132].
The prevalence of HCV infections was reported to be
0.3–0.7% [116–120,133]. The mode of transmission was by
transfusion of blood and blood products in most of the cases
who received these products before the nationwide blood
screening process for HCV had been implemented [134].
Most HCV infections in Turkey are caused by genotype 1b
[134–136]. Currently, the country’s stockpile of blood is
safe, and all donations are serologically screened for HBV,
HCV, and HIV, among other blood-borne pathogens. More-
over, couples are encouraged to be screened for these
viruses before marriage, and those who are found to be
positive are counselled with regard to preventive measures
[121].
Parasitic Infections: Malaria
Malaria has been known since early in Turkish history [46],
and today chloroquine-sensitive Plasmodium vivax is the only
common aetiological agent of the disease throughout the
country [137]. Sporadically, imported cases of Plasmodium fal-
ciparum have been reported [137]. In 1997, c. 35 000 cases
of P. vivax malaria were notiﬁed. The number of infected
cases fell to c. 10 000 in 2002, owing to intensive preventive
efforts, including active and pasive surveillance and vector
control measures (http://www.Saglik.Gov.Tr/tr/belge/1-3416/
sitma-savas-daire-baskanliginin-sitma-ile-ilgili-istati-.Html).
Most of the patients were from Cukurova province, which is
a predominantly irrigated-farming region of south-eastern
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Turkey. During 2009, 84 cases were reported, and in 2010
not a single case was detected [138].
Antibacterial Resistance
High antibiotic resistance rates in Turkey have been linked
to extensive antibiotic consumption [139,140]. In February
2003, the MoH issued a ‘Budget Enforcement Document’
that delineated the antibiotic prescription policy in the coun-
try. According to this regulation, extended-spectrum paren-
teral antibiotics can only be prescribed by the infectious
diseases specialists. If an infectious disease specialist is not
available, only an internist or a paediatrician can make the
prescription. Any antibiotic usage that is not compliant with
this regulation will not be reimbursed by the state [141].
Currently, there are few initial reports on the ﬁnancial gains,
along with decreasing nosocomial infection and resistance
rates, related to the 2003 legislation [142,143].
Antibiotic resistance in community-acquired pathogens
Gram-positive bacteria. . Renal and cardiac sequelae of Strepto-
coccus pyogenes infections continue to be signiﬁcant health
problems in Turkey, although their incidence rates have
declined during the last decade [144–147]. The high fre-
quency of these complications indicates that a lack of early
diagnosis and treatment could be the main problem, rather
than antimicrobial resistance, as low-level antibiotic resis-
tance has been reported only against macrolides and clinda-
mycin in this bacterium [148,149]. On the other hand, the
rate of resistance to tetracycline was reported to be 18% in
both of these studies.
Epidemiological data obtained before the introduction of
the pneumococcal conjugate vaccine PCV7 indicated that 19F
and 6B were the major serotypes recovered from invasive
pneumococcal infections [150]. The data obtained before the
new CLSI breakpoints were established showed that the rate
of non-susceptibility to penicillin was as high as 35%, including
a high-level resistance rate of 7%[139]. The reported resis-
tance rates for other antibiotics included the following: ceftri-
axone, 1%; levoﬂoxacin, 2%; erythromycin, 18%; tetracycline,
19%; trimethoprim–sulphamethoxazole, 39%; chlorampheni-
col, 5%; and rifampicin, 2% [151]. According to the new crite-
ria for penicillin susceptibility, intermediate resistance is 0–3%
and high-level resistance is 0–0.5% for parenteral penicillin in
non-meningeal strains, whereas up to one-third of meningitis
isolates have been reported to be penicillin-resistant in large
series [152–154].
Community-acquired Staphylococcus aureus infections are
rarely reported, and do not seem to be a signiﬁcant problem
[155,156].
Gram-negative bacteria. . Antibiotic resistance does not seem
be a problem in the management of invasive diseases caused
by Haemophilus inﬂuenzae. The most problematic drug is tri-
methoprim–sulphamethoxazole, with one-third of all isolates
being non-susceptible. Other antimicrobials, including b-lac-
tams, quinolones, macrolides, and tetracyclines, seem to be
effective in >90% of H. inﬂuenzae isolates in Turkey (Table 1)
[157–164]. Although ampicillin resistance appears to mainly
correlate with b-lactamase production, 0–2.8% (median, 1%)
of all H. inﬂuenzae isolates were identiﬁed as b-lactamase-
negative ampicillin-resistant strains [158,159,161,163].
High-level antimicrobial resistance was reported in Escheri-
chia coli and Klebsiella spp. isolated from community-acquired
urinary tract infections (CA-UTIs) (Table 2) [165–170]. High-
rate of quinolone resistance seems to compromise the
empirical usage of these antibiotics in CA-UTIs in Turkey
[166–170]. Extended-spectrum b-lactamase (ESBL) produc-
tion by community-acquired E. coli isolates was reported in
5–6% of uncomplicated CA-UTIs [169,171] and in 12–17% of
complicated CA-UTIs [169,171]. The most frequent type of
ESBL detected was CTX-M-15 [171–173].
ESBL production was also reported in community-
acquired isolates of non-typhoidal Salmonella strains [174–
176]. In one study, 29% of Salmonella typhimurium isolates
were found to produce ESBLs, and those strains commonly
co-produced resistance mechanisms for trimethoprim–
sulphamethoxazole and aminoglycosides [177]. Multiresis-
tance patterns were frequently detected in Shigella ﬂexneri
and S. typhimurium [176]. In general, the rate of quinolone
resistance was low. In a recent analysis, among 620 clinical
Salmonella isolates (18 Salmonella typhi and 602 various non-
typhoidal Salmonella), only one Salmonella enteritidis isolate
TABLE 1. Rates of antibiotic resistance in Haemophilus inﬂuenzae isolates from invasive infections in Turkeya [157–164]
AMP A-CL Amp-S CEC CTX CIP TET SXT CLA CLR AZT BLa
3–13 (6) 0–0 (0) 0.5–1 (0.7) 0–2 (0.7) 0–2 (0) 0–3.7 (0) 1–9 (3) 23–32 (26) 2–6 (2) 2–4 (3) 0–3 (0.5) 6–6 (6)
AMP, ampicillin; A-CL, amoxycillin–clavulanate; Amp-S, ampicillin–sulbactam; CEC, cefaclor; CTX, ceftriaxone; CIP, ciproﬂoxacin; TET, tetracycline; SXT, trimethoprim–sulpha-
methoxazole; CLA, chloramphenicol; CLR, clarithromycin; AZT, azithromycin. BLa, b-lactamase activity.
aFigures indicate % range of resistance (median) from published studies.
1060 Clinical Microbiology and Infection, Volume 18 Number 11, November 2012 CMI
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, 1056–1067
was found to be fully resistant to ciproﬂoxacin. However, 75
isolates (12.1%) had MICs between 0.125 and 0.5 mg/L, indi-
cating decreased susceptibility [178].
Antibiotic resistance in the hospital setting
A nationwide nosocomial infection surveillance system (Turk-
ish National Nosocomial Infections Surveillance Network
(UHESA)) was initiated in 2006 by the MoH, and data from
>1200 participating hospitals were collected by the use of
standardized, hand-ﬁlled forms during 2006 and 2007, and
through a web-based notiﬁcation system from 2008 (http://
rshm.gov.tr/enfeksiyon/dosya/rehber.pdf). The 2010 data
from this network are detailed below. It should be noted
that not all participating hospitals are large tertiary-care cen-
tres; many are small-scale regional hospitals. As the UHESA
contains pooled data, these may differ from those reported
in surveillance studies, which are usually performed in ter-
tiary-care, teaching university hospitals.
High antimicrobial resistance rates in nosocomial isolates
have contributed signiﬁcantly to the increasing cost of noso-
comial infections nationwide [179–181]. In Istanbul, the daily
cost of antibiotic use for all hospital-acquired infections in a
tertiary-care, training and research hospital, which pooled
553 patients on the cross-sectional study day, was 2137 USD
[182].
Nosocomial Gram-positive bacteria. . Staphylococcus aureus
remains a signiﬁcant pathogen in Turkish hospitals. According
to the 2010 UHESA data, the pooled mean methicillin resis-
tance rate was 53% for this bacterium (http://www.rshm.gov.
tr/enfeksiyon/dosya/analiz_2010.pdf). In a single-centre
report, the rate of heterogeneously vancomycin-intermediate
Staphylococcus aureus was 18% among 256 isolates [183].
However, a recent study reported a much lower rate [184].
On the other hand, vancomycin-intermediate Staphylococcus
aureus was not detected in a study with 390 methicillin-resis-
tant Staphylococcus aureus isolates [185].
The ﬁrst vancomycin-resistant Enterococcus faecium (VRE)
isolate in Turkey was obtained in 1997 [186]. At the turn of
the new millennium, only sporadic cases of VRE had been
reported [187]. Currently, VRE comprises 11% of all entero-
coccal nosocomial isolates, according to a UHESA report
(http://rshm.gov.tr/enfeksiyon/dosya/rehber.pdf). So far, no
linezolid and daptomycin resistance has been reported for
Staphylococcus aureus and enterococcal isolates [188–191].
Nosocomial Gram-negative bacteria. . Common resistance
problems in tertiary-care hospitals in Turkey include high
rates of ESBL-producing enteric Gram-negative bacteria, and
TABLE 2. Rates of antibiotic resistance in Escherichia coli
and Klebsiella spp. isolates from community-acquired uri-
nary tract infections in Turkey (adapted from [165])
Antibiotics
E. coli Klebsiella spp.
Range (%) Median (%) Range (%) Median (%)
Ampicillin 37–82 55 79–100 91
Ampicillin–sulbactam 15–57 45 42–60 51
Amoxycillin–clavulanate 10–40 26 6–64 41
Cefazolin 7–49 29 100 100
Cefuroxime 5–34 22 20–54 42
Ceftriaxone 2–30 7 5–36 27
Ceftazidime 2–10 6 5–25 25
Cefepime 2–13 10 0–13 8
Trimethoprim–
sulphamethoxazole
12–63 40 16–48 35
Gentamicin 3–47 11 12–30 18
Amikacin 1–32 4 4–33 19
Fosfomycin 0–3 1 NK NK
Nitrofurantoin 0–18 5 10–76 12
Ciproﬂoxacin 6–39 18 6–30 18
Piperacillin–tazobactam 3–17 10 15–35 23
Imipenem 0–3 1 0–5 0
NK, not known.
TABLE 3. Rates (%) of antibiotic resistance among hospital-acquired Gram-negative bacteria in two large surveillance studies
inTurkey [194,196]
Escherichia coli
Klebsiella pneumoniae Pseudomonas aeruginosa
Acinetobacter spp.
HITIT-2a MYSTICb HITIT-2 MYSTIC HITIT-2 MYSTIC HITIT-2 MYSTIC
Ceftriaxone ND 21 ND 41 ND 83 ND 90
Ceftazidime 31 15 36 55 26 54 87 83
Cefepime 27 14 31 22 24 56 76 71
Imipenem 0 1 3 15 30 52 55 33
Cefoperazone–sulbactam 10 ND 25 ND 30 ND 52 ND
Piperacillin–tazobactam 18 16 25 27 18 31 85 84
Ciproﬂoxacin 58 38 18 29 27 54 87 78
Amikacin 5.5 ND 12 ND 23 ND 63 ND
Tobramycin ND 21 ND 55 ND 59 ND 44
ESBL-positive 42 15 41 40 ND ND ND ND
ESBL, extended-spectrum b-lactamase; ND, not determined.
aThe HITIT-2 study was performed in 13 tertiary-care centres in 2007.
bThe MYSTIC study was performed in nine tertiary-care centres in 2000.
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carbapenem resistance in Acinetobacter spp. and Pseudomonas
aeruginosa [192–195]. The data from the 2010 UHESA report
indicated the following overall resistance rates in participat-
ing hospitals: ESBL production in Klebsiella pneumoniae and
E. coli was 45.8% and 40%, respectively; and carbapenem
resistance in Pseudomonas aeruginosa and Acinetobacter bau-
mannii was 31% and 69%, respectively. Two recent multicen-
tre surveillance studies in large tertiary-care university
centres reported resistance data for various Gram-negative
nosocomial pathogens that are generally in accordance with
the resistance patterns described above [194,196] (Table 3).
PER-1, a class A ESBL, has been found to be widespread
in MDR Pseudomonas aeruginosa and A. baumannii [197–199].
Among the carbapenemase-producing bacteria, OXA-48 was
ﬁrst detected in a K. pneumoniae strain in Istanbul in 2001
[200]. Subsequently, the same enzyme was found in other
Enterobacteriaceae [201]. Outbreaks have been described
[202], and apparently these strains have disseminated to
other European countries from Turkey [203]. There is preli-
minary evidence that OXA-48-producing isolates may be cir-
culating in the community [201]. OXA-23, OXA-51 and
OXA-58 were the most common carbapenemases in MDR
A. baumannii isolates from several centres [204,205]. Metallo-
b-lactamases, mainly of the VIM and IMP types, were also
reported in Enterobacteriaceae and Pseudomonas aeruginosa
[201]. The ﬁrst NDM-1 in Turkey was recently reported in a
K. pneumoniae strain isolated from a patient transferred from
Iraq [206].
Conclusions
Although the implementation of intensive vaccination policies
and preventive public health measures has caused a signiﬁ-
cant decline in the prevalence of many important infectious
diseases, several community-acquired infections, including
brucellosis, tularaemia, and CCHF, remain important health
challenges in Turkey. The country has recently adopted a
universal health insurance policy for all citizens. High rates of
antimicrobial resistance in both outpatient and inpatients set-
tings that compromise effective healthcare are prevalent, and
contribute substantially to increased health expenditure by
the state. In response to this, a nationwide resistance surveil-
lance system has recently been initiated, and a restricted
antimicrobial prescription policy has been implemented in all
secondary-care and tertiary-care hospital settings. It is
expected that these actions will have a favourable effect,
leading to a decline in antibiotic resistance in the near future,
but, currently, solid data supporting these expectations are
lacking.
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